Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

114.43
-2.7800-2.37%
Post-market: 114.450.0200+0.02%19:32 EDT
Volume:11.48M
Turnover:1.32B
Market Cap:142.50B
PE:301.13
High:116.98
Open:116.65
Low:113.92
Close:117.21
Loading ...

Daiwa Securities Adjusts Price Target on Gilead Sciences to $104 From $90, Keeps Neutral Rating

MT Newswires Live
·
14 Feb

BUZZ-Ideaya Biosciences falls as quarterly loss widens

Reuters
·
13 Feb

IDEAYA Biosciences Launching Gilead Trial Collaboration to Evaluate Trodelvy, IDE397 Combination in Lung Cancer

MT Newswires Live
·
13 Feb

IDEAYA Biosciences Inc: IDEAYA Is Study Sponsor and Gilead Will Provide Supply of Trodelvy to IDEAYA

THOMSON REUTERS
·
13 Feb

IDEAYA Biosciences Inc: IDEAYA and Gilead Retain Commercial Rights to Their Respective Compounds

THOMSON REUTERS
·
13 Feb

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

PR Newswire
·
13 Feb

Gilead upgraded to Buy from Hold at DZ Bank

TIPRANKS
·
13 Feb

South African Markets - Factors to watch on February 13

Reuters
·
13 Feb

Evercore ISI Remains a Buy on Gilead Sciences (GILD)

TIPRANKS
·
13 Feb

Gilead Sciences: Strong Performance and Growth Potential in HIV and Oncology Segments Boost Buy Rating

TIPRANKS
·
13 Feb

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

Benzinga
·
13 Feb

US STOCKS-S&P 500 falls as hot inflation data hints at fewer rate cuts

Reuters
·
13 Feb

5 ASX ETFs to buy with $5,000 today

MotleyFool
·
13 Feb

Why Gilead Sciences (GILD) Stock Is Trading Up Today

StockStory
·
13 Feb

US Equity Indexes Mixed as Treasury Yields Advance Amid Hot Inflation Report

MT Newswires Live
·
13 Feb

Medicare Reform to Flatten Gilead's Booming HIV Sales

Dow Jones
·
13 Feb